PRLog - Jan. 23, 2013 - Tecan and IBBL (Integrated BioBank of Luxembourg) have successfully co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation, relieving scientific staff from performing this time-consuming task, and significantly increasing the yield of DNA.
The IBBL team with the Freedom EVO
The process of manually isolating the buffy coat from whole blood is traditionally slow, tedious and very dependent on the skill and dexterity of the technician separating the layers. This lengthy and variable element of sampling has been eliminated by automating the procedure on a Freedom EVO 200 platform, optimized to maximize the yield and quality of the buffy coat and minimize the risk of cross-contamination.
Fay Betsou, Chief of Biospecimen Science at IBBL, explained: “The Freedom EVO’s Liquid Handling (LiHa) Arm pipettes the buffy coat layer with very precise orientation and speed, standardizing the process and eliminating technician-to-
To find out more about Tecan’s biobanking solutions, visit www.tecan.com/
For more information please contact
Tecan Trading AG
Cornelia Kegele / Antonietta Allocca
Seestrasse 103, CH-8708 Männedorf
Tel +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12
firstname.lastname@example.org www.tecan.com (https://smtp.kdm-
For more information about IBBL, please visit: www.ibbl.lu.
Press Contact for IBBL
Communications Manager, IBBL
6 rue Nicolas Ernest Barblé
Tel: +352 44 24 64 - 24, Fax: +352 44 24 64 - 64
IBBL (Integrated BioBank of Luxembourg) is an independent, not-for-profit Luxembourg-based biobank dedicated to improving health outcomes for patients by supporting high standards of medical research. IBBL serves as an international centre of excellence in biobanking, and helps to accelerate the introduction of personalised healthcare in Luxembourg. IBBL collects, stores, and analyses biological samples and associated data, which are available to research organisations investigating human diseases. IBBL has built an integrated infrastructure offering biospecimens, data, technologies and biospecimen research to support a successful biomedical research industry in Luxembourg and facilitate rapid translation of discoveries into improved care. IBBL also provides administrative support to the Luxembourg Personalized Medicine Consortium (PMC). With the help of the people of Luxembourg, IBBL catalyses partnerships and supports research that translates today’s discoveries into tomorrow’s healthcare solutions.